DRD2/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma

World Journal of Surgery

Volumn 30, Issue 9, 2006, Pages 1672-1679

  Li, Li ^a   Miyamoto, Masaki ^a   Ebihara, Yuma ^a   Mega, Seiji ^a   Takahashi, Ryo ^a   Hase, Ryunosuke ^a   Kaneko, Hiroyuki ^a   Kadoya, Masatoshi ^a   Itoh, Tomoo ^b   Shichinohe, Toshiaki ^a   Hirano, Satoshi ^a   Kondo, Satoshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; PHOSPHOPROTEIN DARPP 32;

ADULT; AGED; CANCER CLASSIFICATION; CANCER GRADING; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE ASSOCIATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 33748805489     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-006-0035-3     Document Type: Conference Paper

References (30)

1. Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus, the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997;114:205-209.
2. Ando N, Ozawa S, Kitagawa Y, et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232:225-232.
3. Collard JM, Otte JB, Fiasse R, et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001;234:25-32.
4. Komukai S, Nishimaki T, Watanabe H, et al. Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. Surgery 2000;127:40-46.
5. Entschladen F, Lang K, Drell TL, et al. Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother 2002;51:467-482.
6. Lang K, Drell TL IV, Lindecke A, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004;112:231-238.
7. Missale C, Nash SR, Robinson SW, et al. Dopamine receptors from structure to function. Physiol Rev 1998;78:189-225.
8. Hemmings HC Jr, Greengard P, Tung HY, et al. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 1984;310:503-505.
9. Yan Z, Hsieh-Wilson L, Feng J, et al. Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat Neurosci 1999;2:13-17.
10. Montmayeur JP, Bausero P, Amlaiky N, et al. Differential expression of the mouse D2 dopamine receptor isoforms. FEBS Lett 1991;278:239-243.
11. Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 1997;17:8147-8155.
12. Picardo M, Passi S, Nazzaro-Porro M, et al. Mechanism of antitumoral activity of catechols in culture. Biochem Pharmacol 1987;36:417-425.
13. Wick MM. Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells. J Invest Dermatol 1989;92:329-331.
14. Johnson DE, Ochieng J, Evans SL. The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells. Anticancer Drugs 1995;6:471-474.
15. Saha B, Mondal AC, Basu S, et al. Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis. Int Immunopharmacol 2001;1:1363-1374.
16. Ishibashi M, Fujisawa M, Furue H, et al. Inhibition of growth of human small cell lung cancer by bromocriptine. Cancer Res 1994;54:3442-3446.
17. Basu S, Dasgupta PS. Alteration of dopamine D2 receptors in human malignant stomach tissue. Dig Dis Sci 1997;42:1260-1264.
18. Scemama JL, Ruellan C, Clerc P, et al. Dopamine receptors in a human colonic cancer cell line (HT29). Some receptor-related biological effects of dopamine. Int J Cancer 1984;34:675-679.
19. Basu S, Dasgupta PS. Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Dig Dis Sci 1999;44:916-921.
20. Sokoloff P, Riou JF, Martres MP, et al. Presence of dopamine D-2 receptors in human tumoral cell lines. Biochem Biophys Res Commun 1989;162:575-582.
21. Comings DE, Gade-Andavolu R, Cone LA, et al. A multigene test for the risk of sporadic breast carcinoma. Cancer 2003;97:2160-2170.
22. Lemmer K, Ahnert-Hilger G, Hopfner M, et al. Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci 2002;71:667-678.
23. Steinert H, Huch-Boni RA, Boni R, et al. Dopamine-D2 receptor scintigraphy with 123I-iodobenzofuran in malignant melanoma. Nuklearmedizin 1995;34:146-150.
24. Boni R, Lichtensteiger W, Steinert HC, et al. D1 dopamine receptors are not expressed in human melanoma. Melanoma Res 1997;7:117-119.
25. Bodei L, Hofland LJ, Ferone D, et al. In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas. Cancer Biother Radiopharm, 2003;18:895-902.
26. Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab 2004;89:4493-4502.
27. Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004;89:2452-2462.
28. Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999;23:435-447.
29. Ebihara Y, Miyamoto M, Fukunaga A, et al. DARPP-32 expression arises after a phase of dysplasia in oesophageal squamous cell carcinoma. Br J Cancer 2004;91:119-123.
30. Svenningsson P, Nishi A, Fisone G, et al. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 2004;44:269-296.